Condition
Malignant Meningioma
Total Trials
4
Recruiting
1
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
Early P 1 (1)
P 1 (2)
Trial Status
Completed2
Not Yet Recruiting1
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07552233Not ApplicableRecruiting
NK Cell Therapy for Malignant Solid Brain Tumors
NCT07172178Early Phase 1Not Yet RecruitingPrimary
γδ T-PD-1 Ab Cells in the Treatment of Malignant Meningioma
NCT01151670Phase 1Completed
Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Treating Patients With Brain Tumors
NCT01144247Phase 1Completed
Cellular Immunotherapy Study for Brain Cancer
Showing all 4 trials